Cargando…

Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study

BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hanwen, Zhang, Ning, Li, Yaming, Liang, Yiran, Yang, Qifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758869/
https://www.ncbi.nlm.nih.gov/pubmed/33425023
http://dx.doi.org/10.1177/1758835920975603
_version_ 1783627016386379776
author Zhang, Hanwen
Zhang, Ning
Li, Yaming
Liang, Yiran
Yang, Qifeng
author_facet Zhang, Hanwen
Zhang, Ning
Li, Yaming
Liang, Yiran
Yang, Qifeng
author_sort Zhang, Hanwen
collection PubMed
description BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 patients with mucinous carcinoma from 1994 to 2014 were identified. Clinicopathological characteristics were compared using the chi-square test. BCSS curves were generated using the Kaplan–Meier method. The prognostic significance of all demographic and clinicopathological characteristics and treatment patterns were calculated using univariate and multivariate regression analyses. RESULTS: Mucinous carcinoma was demonstrated to be less aggressive than invasive ductal carcinoma and predicted a better prognosis in the Kaplan–Meier analysis (hazard ratios = 0.336, 95% confidence interval: 0.308–0.368, p < 0.001). Univariate and multivariate analyses revealed that chemotherapy did not provide any additional benefit for patients with mucinous carcinoma. Predictors for receiving chemotherapy were younger age, estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-positive status, higher grade, larger tumor size, lymph node involvement, radiation reception, and mastectomy. Further subgroup analysis verified that regardless of the hormone receptor (HR) and lymph node (LN) status, patients did not benefit from chemotherapy. CONCLUSION: Our study showed that patients with HR+/LN– mucinous carcinoma did not benefit from chemotherapy and that chemotherapy could not improve the survival of all subtypes of mucinous carcinoma based on large-scale SEER data. These results support that patients with mucinous carcinoma could be exempt from chemotherapy. Additional research is needed to further evaluate the impact of adjuvant treatments, particularly in patients with favorable histology.
format Online
Article
Text
id pubmed-7758869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77588692021-01-08 Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study Zhang, Hanwen Zhang, Ning Li, Yaming Liang, Yiran Yang, Qifeng Ther Adv Med Oncol Original Research BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 patients with mucinous carcinoma from 1994 to 2014 were identified. Clinicopathological characteristics were compared using the chi-square test. BCSS curves were generated using the Kaplan–Meier method. The prognostic significance of all demographic and clinicopathological characteristics and treatment patterns were calculated using univariate and multivariate regression analyses. RESULTS: Mucinous carcinoma was demonstrated to be less aggressive than invasive ductal carcinoma and predicted a better prognosis in the Kaplan–Meier analysis (hazard ratios = 0.336, 95% confidence interval: 0.308–0.368, p < 0.001). Univariate and multivariate analyses revealed that chemotherapy did not provide any additional benefit for patients with mucinous carcinoma. Predictors for receiving chemotherapy were younger age, estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-positive status, higher grade, larger tumor size, lymph node involvement, radiation reception, and mastectomy. Further subgroup analysis verified that regardless of the hormone receptor (HR) and lymph node (LN) status, patients did not benefit from chemotherapy. CONCLUSION: Our study showed that patients with HR+/LN– mucinous carcinoma did not benefit from chemotherapy and that chemotherapy could not improve the survival of all subtypes of mucinous carcinoma based on large-scale SEER data. These results support that patients with mucinous carcinoma could be exempt from chemotherapy. Additional research is needed to further evaluate the impact of adjuvant treatments, particularly in patients with favorable histology. SAGE Publications 2020-12-18 /pmc/articles/PMC7758869/ /pubmed/33425023 http://dx.doi.org/10.1177/1758835920975603 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Zhang, Hanwen
Zhang, Ning
Li, Yaming
Liang, Yiran
Yang, Qifeng
Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title_full Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title_fullStr Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title_full_unstemmed Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title_short Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
title_sort evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758869/
https://www.ncbi.nlm.nih.gov/pubmed/33425023
http://dx.doi.org/10.1177/1758835920975603
work_keys_str_mv AT zhanghanwen evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy
AT zhangning evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy
AT liyaming evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy
AT liangyiran evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy
AT yangqifeng evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy